Ali Zaheer, Islam Anik, Sherrell Peter, Le-Moine Mark, Lolas Georgios, Syrigos Konstantinos, Rafat Mehrdad, Jensen Lasse D
Department of Medical and Health Sciences, Division of Cardiovascular Medicine, Linköping University, Linköping SE-58183, Sweden.
Department of Materials, Faculty of Engineering, Imperial College London, London, SW7 2AZ, United Kingdom.
Biol Open. 2018 Mar 12;7(3):bio027060. doi: 10.1242/bio.027060.
Therapeutic induction of blood vessel growth (angiogenesis) in ischemic tissues holds great potential for treatment of myocardial infarction and stroke. Achieving sustained angiogenesis and vascular maturation has, however, been highly challenging. Here, we demonstrate that alginate:collagen hydrogels containing therapeutic, pro-angiogenic FGF-2, and formulated as microspheres, is a promising and clinically relevant vehicle for therapeutic angiogenesis. By titrating the amount of readily dissolvable and degradable collagen with more slowly degradable alginate in the hydrogel mixture, the degradation rates of the biomaterial controlling the release kinetics of embedded pro-angiogenic FGF-2 can be adjusted. Furthermore, we elaborate a microsphere synthesis protocol allowing accurate control over sphere size, also a critical determinant of degradation/release rate. As expected, alginate:collagen microspheres were completely biocompatible and did not cause any adverse reactions when injected in mice. Importantly, the amount of pro-angiogenic FGF-2 released from such microspheres led to robust induction of angiogenesis in zebrafish embryos similar to that achieved by injecting FGF-2-releasing cells. These findings highlight the use of microspheres constructed from alginate:collagen hydrogels as a promising and clinically relevant delivery system for pro-angiogenic therapy.
在缺血组织中通过治疗手段诱导血管生长(血管生成)对于心肌梗死和中风的治疗具有巨大潜力。然而,实现持续的血管生成和血管成熟极具挑战性。在此,我们证明含有治疗性促血管生成因子FGF-2并制成微球的海藻酸盐:胶原蛋白水凝胶,是一种用于治疗性血管生成的有前景且与临床相关的载体。通过在水凝胶混合物中用降解较慢的海藻酸盐滴定易溶解和可降解的胶原蛋白的量,可以调节控制嵌入的促血管生成因子FGF-2释放动力学的生物材料的降解速率。此外,我们精心制定了一种微球合成方案,能够精确控制球体大小,而球体大小也是降解/释放速率的关键决定因素。正如预期的那样,海藻酸盐:胶原蛋白微球具有完全的生物相容性,注射到小鼠体内时不会引起任何不良反应。重要的是,从此类微球中释放的促血管生成因子FGF-2的量在斑马鱼胚胎中导致了强大的血管生成诱导,类似于通过注射释放FGF-2的细胞所实现的效果。这些发现突出了使用由海藻酸盐:胶原蛋白水凝胶构建的微球作为用于促血管生成治疗的有前景且与临床相关的递送系统。